INTRODUCTION
============

Keratoacanthoma (KA) is an epithelial tumor that frequently occurs in sun-exposed areas, including the face and lip. It may arise from the derived from pilosebaceous unit, particularly the outer root sheath cells.^[@R1]^ KA is classically described as rapid proliferation of epithelial cells that molds a crateriform architecture containing a central plug of keratin.^[@R2]--[@R4]^ The clinical progression of KA is characterized by rapid enlargement, maturation of the lesion, and spontaneous regression.^[@R4],[@R5]^ The involution phase of KA can take months,^[@R4]^ resulting in surgical excision of the majority of KAs.^[@R6]^ KA cells proliferate rapidly and contain dyskeratosis that is similar to keratin pearls; its histopathological features resemble those of a well-differentiated squamous cell carcinoma (SCC), suggesting it may have the potential for malignant transformation.^[@R7]--[@R10]^ Because the histopathological aspects of KA and SCC are similar, clinical history may be necessary for the correct diagnosis. The most part of studies have focused on the identification of markers that distinguish KA from SCC,^[@R5],[@R9],[@R11]--[@R19]^ but the mechanisms underlying KA pathways are poorly understood. Molecular biology profiling using comparative genomic hybridization (CGH) revealed that KA and SCC rarely share genomic aberrations. Indeed, genomic aberrations are found in 30% to 40% of KAs and 80% of SCCs.^[@R11],[@R12],[@R20]^

The phosphatidylinositol 3-kinase-mammalian target of rapamycin mTOR (PI3K-mTOR) pathway is one of the most common pathways implicated in tumor development and progression, particularly in tumors of epithelial origin.^[@R21]--[@R24]^ PI3K-mTOR signaling leads to the activation of mTORC1 and mTORC2 complexes, which are regulated by the tumor suppressor PTEN (Phosphatase and tensin homolog). PTEN protein, also known as MMAC1 and TEP1, acts as a phosphatase and blocks activation of PI3K-mTOR signaling. Therefore, PTEN functions as a master regulator of tumor proliferation, aggressiveness, and survival.^[@R24]^ The role of the PI3K-mTOR pathway in the pathobiology of KA is poorly understood.

In the present study, we investigated the role of PI3K-PTEN-mTOR pathway in lip KA with immunohistochemistry analysis of pathway representative markers PTEN, pS6, and pAKT. In addition, we analyzed the activation of cellular senescence, as evidenced by expression of the p16^*Ink4*^ senescence marker and the proliferation profile using Ki-67 index.

MATERIALS AND METHODS
=====================

Specimens
---------

Hematoxylin and eosin (H&E) staining was performed on formalin-fixed and paraffin-embedded sections of KAs from the lip. Specimens were obtained between 1989 and 2012 from the archives of the diagnosis center of the Oral Pathology Department in the School of Dentistry at the Federal University of Rio Grande do Sul, and the Pathology Service in the Hospital de Clinicas de Porto Alegre in Brazil with written consent from patients (Human Research Ethics Committee approval n. 802.108). Histological diagnoses and descriptive attributes of 9 cases were reviewed (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Lip KA samples were from 56% woman and 44% men, ranging in age from 48 to 77 years (mean age: 63.8 years) (Table [2](#T2){ref-type="table"}). Detailed histological analyses were performed by 2 experienced pathologists (CHS and MM). After careful analysis, histological images were captured with a QImaging EXi Aqua monochrome digital camera and Nikon Eclipse 80i Microscope (Nikon, Melville, NY). The histological diagnostic criteria used were presence of well-delimited hyperplastic and crateriform endophytic or exophytic epithelia, cup-shaped central crater containing keratin, large cells with prominent nucleoli and eosinophilic ground-glass cytoplasm with lack of anaplasia, basaloid layer in proliferating endophytic lobules, and sharp outline between tumor nests and the stroma as previously described.^[@R3]^

###### 

Histological Features are Depicted for Each Case of Keratoacanthoma
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Descriptive Attributes of the Cases
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IMMUNOHISTOCHEMISTRY
====================

The tissue specimens were fixed in 10% formalin and embedded in paraffin by standard procedures. Immunohistochemical (IHC) assays were performed on 5-μm sections using the streptavidin-biotin and 3,3-diaminobenzidine (DAB) method, as previously described by our research group.^[@R25]^ Briefly, antigen retrieval was performed using either 10 mMol/l sodium citrate buffer (pH 6) or a preheated solution of 1 mMol/l EDTA/Tween 20 (pH 9.0). The sections were incubated overnight at 4°C with the following primary antibodies: Anti-human PTEN (clone 6H2.1, mouse monoclonal antibody \[mAb\], Cascade BioScience, Winchester, MA), anti-human Ki-67 (Clone MIB-1, mouse mAb, DAKO, Houston, TX), p70 S6 Kinase (clone 49D7, rabbit mAb, Cell Signaling, Danvers, MA), phospho-AKT (Ser473, rabbit mAb, Cell Signaling, Danvers, MA), and p16^*INK4*^ (clone G175--405, mouse mAb, BD Pharmingen, San Jose, CA). Isotype controls (mouse IgG; rabbit IgG, Santa Cruz Biotechnology, Dallas, TX) and/or no primary addition were used as negative controls. pS6, pAKT^Ser473^ and PTEN brown cytoplasmic expression and p16^*INK4*^ nuclear (N) and cytoplasmic (C) stain were considered positive labeling. Each antibody was assigned a score representing the percentage of positive cells: 0 (0%--10%), 1 (10%--39%), 2 (40%--69%), 3 (70%--100%) as previous described.^[@R26],[@R27]^

Ki-67 Proliferative Index Quantification
----------------------------------------

Ki-67 index was determined as previously described by Tang et al.^[@R28]^ Tissue samples were photographed using a 20X objective, and 5 to 10 random independent fields were assessed using Image J software. Ki-67-positive nuclear stains were analyzed in tumor and in the non-tumoralepithelia. Labeling index (LI) was determined by counting the labeled nuclei. The results were expressed as percentage of positively stained tumor cells among the total number of tumor cells.

Statistical Analysis
--------------------

Statistical analyses were performed by Student *t* test using GraphPad Prism 5.00 (GraphPad Software, San Diego, CA). Spearman rank correlation test was used to measure the strength of correlation between variables (Ki-67 and PTEN). *P* value ≤0.05 was considered statistically significant. Significant differences were noted by asterisks or *P* values (^∗^*P* ≤ 0.05, ^∗∗^*P* ≤ 0.01, ^∗∗∗^*P* ≤ 0.001, and NS (*P* \> 0.05, not significant)\].

RESULTS
=======

Histological Characteristics
----------------------------

All tumors analyzed in this study had clinical aspects of KA, including sessile and dome-shaped nodules and a central plug of keratin (Figure [1](#F1){ref-type="fig"}A). The epithelial tumor cells below the craters appeared mature with occasional dyskeratosis (ie, premature or abnormal individual cell keratinization) deep in the lesion (Figure [1](#F1){ref-type="fig"}B). As depicted in Figure [1](#F1){ref-type="fig"}C and Table [1](#T1){ref-type="table"}, the lesions had a dense chronic inflammatory infiltrate that was restricted to the underlying stroma. Actinic elastosis was a common alteration found below the adjacent epithelium in all analyzed samples. Other observed features included hyperchromatism (ie, nuclear darkening) and sporadic mitotic figures. Abnormal mitotic figures (eg, tripolar or star shaped mitosis) were absent.

![Keratoacanthoma histological features. (A) (H&E, 40×) Low-power view revealing the morphological aspects of keratoacanthoma, such as well-delimited hyperplastic, crateriform endophytic or exophytic epithelia with a central keratin-containing crater and (B) presence of sharp outline between tumor nests and the stroma (outline), and tumor cells with prominent nucleoli and eosinophilic ground-glassy cytoplasm. (C) Microscopic view of the keratoacanthoma shows intense chronic inflammatory cell infiltrate (arrows) within the connective tissue and juxtaposed to the tumoral epithelial cells (H&E, 200×). Actinic elastosis are present next to the lesion (H&E, 200×) and nuclear hyperchromatism (darkening of nucleus; outline; H&E, 200×) are observed in keratoacanthomas.](medi-94-e1552-g003){#F1}

mtorc1 is Active in Lip KA
--------------------------

Activation of mTORC1 results in phosphorylation of S6 (pS6). Activation of mTORC2 results in phosphorylation of AKT at serine 473 (pAKT^**Ser473**^). Thus, when mTORC2 is not functional, a negative feedback loop blocks AKT full activation (Figure [2](#F2){ref-type="fig"}A). The majority of KA tumor cells, particularly cells at the tumor core, stained positive in the cytoplasm for pS6, indicating activation of mTORC1 signaling (Figure [2](#F2){ref-type="fig"}B and Table [3](#T3){ref-type="table"}). In contrast, tumor cells were negative for pAKT^**Ser473**^, indicating mTORC2 is not active in KA (Figure [2](#F2){ref-type="fig"}B and Table [3](#T3){ref-type="table"}).

![mTORC1 is active in keratoacanthomas. (A) Schematic representation of the PI3K/mTOR pathway showing that activation of S6 (phospho-S6 or pS6) results from mTORC1 complex activation, whereas phosphorylation of AKT at Ser 473 (pAKT^**Ser473**^) results from a feedback loop triggered mTORC2 complex activation. A negative feedback loop causes repression of pAKT activation when mTORC2 is suppressed. (B) Representative microphotograph of immunostaining for pS6 and pAKT^**Ser473**^ in keratoacanthomas. Note that tumor cells are positive for pS6 in the cytoplasm (IHC-200×; insert 400×).](medi-94-e1552-g004){#F2}
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Immunohistochemical Analyses and KA
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Tumor Suppressor PTEN Correlates With Reduced Proliferation in KA
-----------------------------------------------------------------

Here we showed that nontumoral epithelia displayed significant less proliferation (mean: 19.48% ± 2.67%) than KA (tumor) cells (mean 46.87% ± 7.78%) (*P* = 0.0043) (Figure [3](#F3){ref-type="fig"}A). Note that cell division is higher in KA proliferative phase (mean 72.57% ± 4.13%) compared with well developed phase (mean 34.02% ± 9.97%) (*P* = 0.0063) (Figure [3](#F3){ref-type="fig"}A). Nuclear Ki-67 is a proliferation marker present in all active phases of the cell cycle and commonly observed in the edges of KA (Figure [3](#F3){ref-type="fig"}B). Cytoplasmic PTEN was highly expressed in 66.6% of KA cases (Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}C), and notably, these were well developed or mature KAs. Low PTEN expression was found on early or proliferative phase of KAs (Figure [3](#F3){ref-type="fig"}D). This inverse correlation of PTEN of expression and proliferation was statistically significant in KA (*r* = −0.82, *P* = 0.0066) (Figure [3](#F3){ref-type="fig"}D).

![Phosphatase and tensin homolog (PTEN) is activated on Keratoacanthomas and inversely correlates with tumor cell proliferation. (A) Keratoacanthoma tumor cells and non-tumor epithelium were analyzed for nuclear Ki-67. (B) Representative example of Ki-67 staining in keratoacanthomas (Ki-67 IHC - 200×). **C.** Representative example of PTEN stain in keratoacanthomas (PTEN IHC - 200×). (D) Graphic representation of decreased proliferation in keratoacanthomas positive for PTEN ^(∗∗^*P* ≤ 0.01).](medi-94-e1552-g006){#F3}

Cellular Senescence Programs are Active in KA
---------------------------------------------

Senescence is a biological process by which cells cease to divide, adopting a flattened morphology. During this process, inactivation of suppressor elements leads to enhanced expression of p16^*INK4*^.^[@R29]^ Interestingly, KA cells had high expression of p16^*INK4*^ at the cytoplasm and nucleus (Table [3](#T3){ref-type="table"} and Figure [4](#F4){ref-type="fig"}), suggesting that activation of cellular senescence is a protective mechanism against persistent stimulation of growth-associated pathways. These findings suggest that KA maturation and regression may be a consequence of the activation of cellular senescence programs.

![A tumor senescence mechanism is activated in keratoacanthomas. The microphotograph is a representative example of the p16^*Ink4*^ tumor suppressor and senescence marker identified as nuclear and cytoplasmic labeling in keratoacanthoma tumor cells (p16^*Ink4*^ IHC -- 200× and insert - 400×).](medi-94-e1552-g007){#F4}

DISCUSSION
==========

Our findings showed that KA has active mTORC1, but not mTORC2, signaling. These are part of the PI3K-mTOR pathway, one of the most altered signaling pathways in cancer.^[@R21],[@R22],[@R24]^ Activated PI3K increases phosphatidylinositol 3,4,5-trisphosphate (referred to as PIP3, PtdIns(3,4,5)P, or PI(3,4,5)P3), leading to the activation of AKT and mTORC complexes, mTORC1 and mTORC2. Primary activation of AKT (phosphorylation on threonine 308) leads to mTORC1 activation. Interestingly, mTORC1 function is related to cell cycle progression, growth, protein synthesis, lipid synthesis, and autophagy.^[@R30]^ (Figure [2](#F2){ref-type="fig"}A). An additional level of complexity involves an enhanced AKT activation. mTORC2 promotes a feedback loop activation of AKT through phosphorylation on Ser 473, which may be related to actin reorganization and tumor cell invasion.^[@R30],[@R31]^ Thus, one may expect that mTORC2 activity will be higher in malignant tumors compare to benign ones.^[@R32]^ It is remarkable that KA was positive to pS6 but not pAKT^**Ser473**^, indicating that mTORC1, but not mTORC2, is functioning in KA. Interestingly, these findings suggest that the molecular signaling involved in KA development and regression is closely related to growth and autophagy rather than aggressive behavior and invasion.

We also observed accumulation of tumor suppressors, including PTEN, in KA. Owing to its phosphatase activity, PTEN is a true tumor suppressor that opposes oncogenic kinases.^[@R21],[@R22]^ PTEN removes a phosphate from PIP3, opposing the activation of PI3K and serving as a negative regulator of the PI3K-mTOR pathway.^[@R24]^ Loss of PTEN is associated with malignant transformation and aggressive behavior in multiple tumors, including breast, prostate, and head and neck cancer.^[@R21]--[@R24],[@R27],[@R33]^ Notably, the presence of PTEN in KA suggests that activation of tumor suppressor machinery prevents cellular transformation. This observation is supported by the correlation between PTEN expression and reduced proliferation rates.

Even when PTEN is lost in KA, the tumor activates additional tumor suppressor signaling circuitries, including p53/p21^WAF^ and p16^*INK4*^.^[@R34]^ p16^*INK4*^ is a tumor suppressor protein that plays a major role in cell cycle regulation by decelerating cell progression from the G1 to S phase (reviewed in).^[@R35]^ Tumor suppressor and aging biomarker p16^*INK4*^ induces cellular senescence as a mechanism for halting proliferation and preventing malignant transformation; therefore, oncogene-induced senescence (OIS) occurs in benign tumors, but is restricted in advanced malignant tumors. Cellular senescence constitutes an irreversible process triggered by conditions that cause cellular stress, such as DNA-damage, exposure to cytotoxic drugs and oxidative stress, telomerase dysfunction, aberrant oncogene-induced proliferative signals, and oncogene-induced senescence.^[@R35]^ Therefore, it is clear that KA has numerous mechanisms that help in maintaining its benign behavior and long-term involution. The establishment of OIS requires an initial wave of high proliferation, followed by an irreversible growth arrest known as cellular senescence associated with the tumor suppressors, such as PTEN and p16^*INK4*^.^[@R35]--[@R37]^ KA seams to follow this sequential pattern during its developmental phases (ie, proliferative, mature/well-developed, and regression stages), which are characterized by a high proliferation, followed by expression of tumor suppressor PTEN and growth arrest. Noteworthy, the tumor suppressor p16^*INK4*^ is present during most of KA stages.

p16^*INK4*^ expression is upregulated after mild ultraviolet B irradiation exposure,^[@R38],[@R39]^ and in innumerous lesions including seborrheic keratosis, actinic keratosis, KA, and SCC, which makes difficult the use of p16^*INK4*^ as biomarker for differential diagnosis.^[@R19],[@R40]--[@R44]^ Others found the association of Ki-67 and p16 with identification of premalignant lesion in oral, cervical, anal melanotic and others lesions.^[@R44]--[@R46]^ The use of p16^*INK4*^ as prognostic maker is being explored. Interesting, the high expression and nuclear cellular localization of p16^*INK4*^ may indicate it is associated with a favorable prognosis.^[@R47],[@R48]^ Notably, our results showed that p16^*INK4*^ was highly expressed in the nucleus of KA cells.

One of our study limitations was the reduced number of study cases. KA occurs mainly in sun-exposed hairy skin and the oral lesions are infrequent. It is estimated by the World Health Organization that \<8% of the lesions occur in the lip. It is not completely understood the differences among KA occurring on the lip and others sites. Although the lip is hairless, recent work showed that lip KA originates from outer root sheath of pilosebaceous units present next to the vermilion border.^[@R1]^ Future studies may also include comparisons with SCC lip cases and KA using marker for the PI3K-mTOR pathway, once that there are innumerous morphological similarities between KA and SCC of the lip that makes its histological diagnosis challenging, although their clinical and biological behaviors are distinct. Genetic alterations and altered molecular pathways, such as BRAF, NFκB, FOS, p27, and matrix metalloproteinases, among others, are associated with KAs.^[@R11],[@R12],[@R34],[@R49]--[@R54]^ A better understanding of the pathways involved in the development and progression of KA is necessary for understanding its biological behavior and may influence treatment options in the future. KA treatment options depend on the location and size of the lesion. Complete surgical excision is commonly recommended as first-line therapy.^[@R7],[@R55]^ Treatment with vemurafenib, methotrexate, and other nonsurgical therapies have been reported.^[@R2],[@R55]--[@R60]^ mTOR inhibitors, such as rapamycin and its analogs, selectively target the mTOR pathway and are FDA-approved for cancer therapy. Additional inhibitors that target PI3K, mTORC1, and mTORC2 are in clinical trials.^[@R24],[@R61]--[@R63]^ mTOR inhibitors that specifically target mTORC1 may be viable therapeutic strategies for KA.

In summary, here we analyzed the expression of key proteins involved in the activation of the PI3K-mTOR pathway in lip KA. We found that this pathway is partially activated through mTORC1, but not mTORC2. Additionally, KA expressed high levels of PTEN and reduced rates of proliferation. Even when PTEN is lost, we found activation of cellular senescence, as evidenced by expression of the p16^Ink4^ senescence marker. Therefore, the PI3K-mTOR pathway plays an important role in KA progression by regulating proliferation and activation of oncogenic-induced senescence.

Abbreviations: c = cytoplasm, CGH = comparative genomic hybridization, DAB = 3,3-diaminobenzidine, H&E = hematoxylin and eosin, IHC = Immunohistochemistry, KA = keratoacanthoma, LI = labeling index, mAb = monoclonal antibody, n = nucleus, OIS = oncogene induced senescence, pAKT^Ser473^ = phosphorylation of AKT at serine 473, PI3K-mTOR = phosphatidylinositol 3-kinase - mammalian target of rapamycin mTOR, PIP3 = phosphatidylinositol 3,4,5-trisphosphate, pS6 = phosphorylation of S6, PTEN = Phosphatase and tensin homolog, *r* = *Spearman correlation coefficient* , SCC = squamous cell carcinoma.
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